Accelerated Development of Vaccine benefit-risk Collaboration in Europe
Goal of cialis generic sale project is to develop a blueprint for a framework capable of rapidly delivering reliable data on the benefits and risks of vaccines. The framework would help health professionals, regulatory agencies, public health institutions and the general public make informed decisions on immunisation. €10.8 million project represents unique collaboration between key players in sector, including European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA), national public health and regulatory bodies, vaccine manufacturers, SMEs, and academic institutions.
ADVANCE – Work Package 3 – Data sources for rapid and integrated benefit-risk monitoring
Lead: University of Surrey Co-Lead: Sanofi Pasteur
The purpose of WP3 is to identify the data sources across Europe that can be harnessed to conduct comprehensive and rapid vaccine benefit-risk monitoring, and enable innovative research to be conducted. The WP intends to leave a legacy in terms of:
1. Catalogue and where to buy cheap nolvadex online description of data sources available and of organisations willing to share data for open framework investigations. These data sources and their current suitability for vaccine-related research (as defined within the consortium) will be detailed in a catalogue.
2. An ethics and privacy guide for investigators who might want to use the data.
3. Technical guide for investigators looking to conduct vaccine effectiveness and safety studies to help steer them through the data collection, linkage and integration requirements of patio.lcc.uma.es a vaccine investigation and transformation to the http://www.body-psychotherapy.org.uk/viagra-online-fedex-overnight-shipping common data model.
WORK PACKAGE 3 – KICK OFF MEETING
12 November 2013 @ RCGP, London
- WP3 KOM Introduction [pdf]
- WP3 Partner Presentations [pdf]
- WP3 Task 3.1 – Requirement analysis and expert use cases[pdf]
- WP3 Task 3.2 – Identifying candidate data sources for vaccine benefit risk studies [pdf]
- WP3 Task 3.3 – Defining and describing the privacy and ethics issues [pdf]
- Breakout session – Use Cases- Outcome report [pdf]
Use Cases – Resources